EPElizaveta V. Pankratova

Elizaveta V. Pankratova

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Elizaveta V. Pankratova has a total of 27 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    XMU-MP-1, Inhibitor of STE20-like MST1/2 Kinases of the Hippo Signaling Pathway, Suppresses the Cell Cycle, Activates Apoptosis and Autophagy, and Induces Death of Hematopoietic Tumor Cells

    by Alexander G. Stepchenko, Sofia G. Georgieva, Elizaveta V. Pankratova

    Background/Objectives: Currently, there is limited knowledge on the molecular mechanisms of the “non-canonical” Hippo signaling pathway in hematopoietic tumor cells. We have shown that targeting the MST1/2 kinases, which are the key molecules in this signaling pathway, may be an effective approach to the treatment of hematologic tumors. Methods: The methods used in this study include cell growth assays, caspase assays, Western blot hybridizations, flow cytometry, and whole-transcriptome analyses. These methods allowed us to better understand the molecular pathways at play. Results: Our results showed that XMU-MP-1, an inhibitor of MST1/2 kinase, specifically reduces the viability of hematopoietic cancer cells but not breast cancer cells. It effectively inhibits the growth of the tumor B- and T-cell lines by blocking cell cycle progression, mainly during the G2/M phase, inducing apoptosis and autophagy. XMU-MP-1 treatment led to increased caspase 3/7 activity and increased levels of the cleaved PARP protein. Levels of the LC3-II protein were also shown to be increased, while the level of p62 decreased. These changes are associated with apoptosis and autophagy, respectively. RNA-seq analysis has demonstrated that XMU-MP-1 suppressed the expression of cell cycle regulators, such as E2F, and cell division cycle genes CDC6,7,20,25,45; cyclins A2,B1,B2, and cyclin-dependent kinases. At the same time, it increased the expression of genes involved in apoptosis, autophagy, and necroptosis. Conclusions: Combinations of growth assays, caspase assays, Western blotting, and RNA-seq have shown that the dramatic reduction in the number of hematopoietic tumor cells after treatment with XMU-MP-1 is due to both cytostatic and cytotoxic effects. The use of MST1/2 kinase inhibitors could be highly promising for complex therapy of hematological tumors.


  • Inhibition of MST1/2 Kinases of the Hippo Signaling Pathway Enhances Antitumor Chemotherapy in Hematological Cancers

    by A. G. Stepchenko, Yu. V. Ilyin, S. G. Georgieva, E. V. Pankratova

    Primary drug resistance of tumor cells or resistance acquired during treatment is among the main factors that significantly limit the efficacy of antitumor chemotherapy, along with severe side effects depending on the drug dose. To increase the efficacy, chemotherapeutics can be used in combination with substances that modulate the functions of cell signaling pathways. In this work, the substance XMU-MP-1, an inhibitor of key MST1/2 kinases of the Hippo signaling pathway, was shown to enhance the antitumor activity of two genotoxic chemotherapeutics, etoposide and cisplatin, against Namalwa Burkitt’s B-cell lymphoma cells. XMU-MP-1 increased the cytotoxicity of the agents and significantly reduced their CTD50. The drug efficacy is therefore possible to increase significantly, and a therapeutic effect might be achieved at a lower drug concentration to reduce the likelihood of life-threatening side effects.


  • Open Access

    Suppression of OCT-1 in Metastatic Breast Cancer Cells Reduces Tumor Metastatic Potential, Hypoxia Resistance, and Drug Resistance

    by Alexander G. Stepchenko, Elizaveta V. Bulavkina, Tatiana N. Portseva, Sofia G. Georgieva, Elizaveta V. Pankratova

    OCT-1/POU2F1 is a ubiquitously expressed transcription factor. Its expression starts at the earliest stage of embryonic development. OCT-1 controls genes involved in the regulation of differentiation, proliferation, cell metabolism, and aging. High levels of OCT-1 transcription factor in tumor cells correlate with tumor malignancy and resistance to antitumor therapy. Here, we report that suppression of OCT-1 in breast cancer cells reduces their metastatic potential and drug resistance. OCT-1 knockdown in the MDA-MB231 breast cancer cells leads to a fivefold decrease (p < 0.01) in cell migration rates in the Boyden chamber. A decrease in the transcription levels of human invasion signature (HIS) genes (ARHGDIB, CAPZA2, PHACTR2, CDC42, XRCC5, and CAV1) has been also demonstrated by real-time PCR, with high expression of these genes being a hallmark of actively metastasizing breast cancer cells. Transcriptional activity of ATF6 response elements is significantly reduced in the cell lines with decreased OCT-1 expression, which results in lower levels of adaptive EPR stress response. OCT-1 knockdown more than two times increases the MDA-MB231 cell death rate in hypoxia and significantly increases the doxorubicin or docetaxel-treated MDA-MB231 cell death rate. Our findings indicate that OCT-1 may be an important therapeutic target and its selective inhibition may have significant therapeutic effects and may improve prognosis in breast cancer patients.


  • POU2F1 (Oct-1) Differently Autoregulates the Alternative Promoters of Its Own Gene by Binding to Different Regulatory Sites

    by E. V. Pankratova, T. N. Portseva, A. A. Makarova, B. M. Lyanova, S. G. Georgieva, A. G. Stepchenko

    The POU2F1 gene, which plays an important role in regulating the mammalian genome and development, has both a ubiquitous (U) and a tissue-specific (L) promoter and is subject to intricate regulation. Regions of POU2F1 gene were found to contain multiple binding sites for its product POU2F1 (Oct-1), a transcription factor. Interspecies homology in these regions was found to exceed 90% among the human, mouse, rat, pig, and dog genomes, almost all of the Oct-1 binding sites being identical. Some of the sites cluster in the vicinity of each of the two alternative promoters, while others are in the 5' noncoding region 6 kb upstream of the transcription start site. The presence of Oct-1 at the sites was demonstrated by chromatin immunoprecipitation and the electrophoretic mobility shift assay (EMSA). A POU2F1 knockdown activated the U promoter and downregulated the L promoter in Namalwa cells, while Oct-1 overexpression exerted an opposite effect. Thus, Oct-1 acts via negative feedback to autoregulate the U promoter through low-affinity Oct-1 binding sites and positive feedback to autoregulate the L promoter through high-affinity canonical (oct) sites when increasing in concentration in a natural context.


  • Open Access

    Primate-specific stress-induced transcription factor POU2F1Z protects human neuronal cells from stress

    by Alexander G. Stepchenko, Tatiana N. Portseva, Ivan A. Glukhov, Alina P. Kotnova, Bella M. Lyanova, Sofia G. Georgieva, Elizaveta V. Pankratova

    The emergence of new primate-specific genes is an essential factor in human and primate brain development and functioning. POU2F1/Oct-1 is a transcription regulator in higher eukaryotes which is involved in the regulation of development, differentiation, stress response, and other processes. We have demonstrated that the Tigger2 transposon insertion into the POU2F1 gene which occurred in the primate lineage led to the formation of an additional exon (designated the Z-exon). Z-exon-containing primate-specific Oct-1Z transcript includes a short upstream ORF (uORF) located at its 5’-end and the main ORF encoding the Oct-1Z protein isoform (Pou2F1 isoform 3, P14859-3), which differs from other Oct-1 isoforms by its N-terminal peptide. The Oct-1Z-encoding transcript is expressed mainly in human brain cortex. Under normal conditions, the translation of the ORF coding for the Oct-1Z isoform is repressed by uORF. Under various stress conditions, uORF enables a strong increase in the translation of the Oct-1Z-encoding ORF. Increased Oct-1Z expression levels in differentiating human neuroblasts activate genes controlling stress response, neural cell differentiation, brain formation, and organogenesis. We have shown that the Oct-1Z isoform of the POU2F1/Oct-1 transcription factor is an example of a primate-specific genomic element contributing to brain development and cellular stress defense.


  • Open Access

    The regulatory interplay between Oct-1 isoforms contributes to hematopoiesis and the isoforms imbalance correlates with a malignant transformation of B cells

    by Elizaveta V. Pankratova, Alexander G. Stepchenko, Irina D. Krylova, Tatiana N. Portseva, Sofia G. Georgieva

    // <![CDATA[ $('.header-date').hide();$('#titleAuthors').hide();$('#abstractHeader').hide(); // ]]> Elizaveta V. Pankratova1, *, Alexander G. Stepchenko1, *, Irina D. Krylova1, Tatiana N. Portseva1, 2 and Sofia G. Georgieva1 1Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow, Russia 2Pirogov Russian National Research Medical University, Moscow, Russia *These authors have contributed equally to the work Correspondence to: Sofia G. Georgieva, email: sonjag@molbiol.edu.ru Elizaveta V. Pankratova, email: pank@eimb.ru Keywords: POU2F1; isoforms; hematopoietic cells differentiation; molecular therapeutic target Abbreviations: POU2F1, POU domain class 2 transcription factor 1 Received: April 01, 2018 Accepted: May 31, 2018 Published: July 06, 2018 ABSTRACT Oct-1(POU2F1) is a DNA-binding transcription regulator and its level being highly increased in many human cancers. Oct-1 is present in the human cells as a family of functionally different isoforms which are transcribed from alternative promoters. Here, we have demonstrated that expression patterns of Oct-1 isoforms change during differentiation of hematopoetic progenitor cells (CD34+) (HPCs) to the B (CD19+) and T (CD3+) cells. While Oct-1L is expressed at a high level in the CD34+ HPCs, its expression level drops dramatically during the T-cell differentiation, although remains nearly the same in B-cells. We have described the novel human Oct-1R isoform which is conserved in mammals and is B cell-specific. Oct-1R was found in B cells, but not in HPCs. Oct-1R is transcribed from the same promoter as Oct-1L, another lymphocyte-specific isoform. Overexpression of Oct-1R and Oct-1L in the Namalwa cells leads to the repression of many genes involved in B-lymphocyte differentiation and signal transduction. Thus these isoforms may regulate the particular stages of development of normal B cells and maintain their proper differentiation status. However the extremely high level of Oct-1L isoform observed in the B-lymphoblast tumor cell lines indicated that the excess of Oct-L seem likely to considerably decrease the differentiation ability of these cells. Oct-1 may serve as a therapeutic target for many tumors, but it should be noted that in a tumor the content of a certain isoform Oct-1, rather than the total Oct-1 protein, can be increased.


  • Open Access

    Different N-terminal isoforms of Oct-1 control expression of distinct sets of genes and their high levels in Namalwa Burkitt's lymphoma cells affect a wide range of cellular processes

    by Elizaveta V. Pankratova, Alexander G. Stepchenko, Tatiana Portseva, Vladic A. Mogila, Sofia G. Georgieva

    Oct-1 transcription factor has various functions in gene regulation. Its expression level is increased in several types of cancer and is associated with poor survival prognosis. Here we identified distinct Oct-1 protein isoforms in human cells and compared gene expression patterns and functions for Oct-1A, Oct-1L, and Oct-1X isoforms that differ by their N-terminal sequences. The longest isoform, Oct-1A, is abundantly expressed and is the main Oct-1 isoform in most of human tissues. The Oct-1L and the weakly expressed Oct-1X regulate the majority of Oct-1A targets as well as additional sets of genes. Oct-1X controls genes involved in DNA replication, DNA repair, RNA processing, and cellular response to stress. The high level of Oct-1 isoforms upregulates genes related to cell cycle progression and activates proliferation both in Namalwa Burkitt's lymphoma cells and primary human fibroblasts. It downregulates expression of genes related to antigen processing and presentation, cytokine-cytokine receptor interaction, oxidative metabolism, and cell adhesion, thus facilitating pro-oncogenic processes.


  • New mRNA isoform of Oct-1 transcription factor is transcribed from alternative promoter

    by I. D. Krylova, T. N. Portseva, S. G. Georgieva, A. G. Stepchenko, E. V. Pankratova

    The Oct-1 transcription factor belongs to a family of highly conserved POU domain proteins that participate in the regulation of housekeeping and tissue-specific gene expression. Several isoforms of Oct-1 were described previously. We have found the new alternative promoter of Oct-1 gene and the corresponding mRNA Oct-1X. This mRNA encodes the alternative Oct-1 isoform, which has a truncated N-terminus compared to Oct-1A or Oct-1L isoforms. We explored the expression pattern of this isoform in human tissues and cell lines and demonstrated that it is ubiquitously expressed, but its expression strongly varies in different tissues. Using cotransfection and double luciferase assay, we have demonstrated that Oct-1X is the activator of housekeeping (histone H2B) and tissue-specific genes (B29) transcription.


  • RNA editing in eukaryotic genome expression

    by E. V. Pankratova, A. G. Stepchenko

    The present review surveys the available data on the involvement of adenine deamination in RNA molecules in the formation of structurally and functionally diverse RNA and protein subforms in...


  • Alternative promoters in expression of genetic information

    by E. V. Pankratova

    Many genes are known to have several promoters. The contribution of alternative promoters to the structural and functional diversity of protein isoforms in eukaryotic cells is considered, including their role in synthesis of identical proteins from different mRNAs, generation of protein isoforms with different and even opposite functions, expression of housekeeping genes, and the variation of the recognition domains of adhesion proteins and receptors. In some cases, alternative promoters allow one gene to produce mRNAs with different open reading frames and, consequently, proteins with no amino acid sequence homology.